158 related articles for article (PubMed ID: 31628681)
41. Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia.
Rădulescu C; Bacârea A; Huțanu A; Gabor R; Dobreanu M
Mediators Inflamm; 2016; 2016():3027363. PubMed ID: 27799724
[TBL] [Abstract][Full Text] [Related]
42. Correlations between complement system's activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia.
He Y; Xu B; Song D; Yu F; Chen Q; Zhao M
Hypertens Pregnancy; 2016 Nov; 35(4):499-509. PubMed ID: 27315511
[TBL] [Abstract][Full Text] [Related]
43. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
[TBL] [Abstract][Full Text] [Related]
44. MMP-14 aggravates onset of severe preeclampsia by mediating soluble endoglin release.
Zhang XH; Zhang HY; Lu S; Jiang LL; Wu J; Yang YL; Zhang SA
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1209-1215. PubMed ID: 29565476
[TBL] [Abstract][Full Text] [Related]
45. Autoantibodies isolated from patients with preeclampsia induce soluble endoglin production from trophoblast cells via interactions with angiotensin II type 1 receptor.
Kobayashi Y; Yamamoto T; Chishima F; Takahashi H; Suzuki M
Am J Reprod Immunol; 2015 Apr; 73(4):285-91. PubMed ID: 25376533
[TBL] [Abstract][Full Text] [Related]
46. Serum protein marker panel for predicting preeclampsia.
Cui L; Shu C; Liu Z; Tong W; Cui M; Wei C; Tang JJ; Liu X; Hai H; Jiang J; He J; Zhang DY; Ye F; Li Y
Pregnancy Hypertens; 2018 Oct; 14():279-285. PubMed ID: 29395656
[TBL] [Abstract][Full Text] [Related]
47. Angiogenic factors and preeclampsia.
Tjoa ML; Levine RJ; Karumanchi SA
Front Biosci; 2007 Jan; 12():2395-402. PubMed ID: 17127249
[TBL] [Abstract][Full Text] [Related]
48. Prediction of preeclampsia based on maternal serum endoglin level in women with pregestational diabetes mellitus.
Kapustin RV; Kopteeva EV; Alekseenkova EN; Korenevsky AV; Smirnov IV; Arzhanova ON
Hypertens Pregnancy; 2022; 41(3-4):173-180. PubMed ID: 35475412
[TBL] [Abstract][Full Text] [Related]
49. Correlation between maternal serum-amniotic fluid anti-angiogenic factors and uterine artery Doppler indices.
Zafer E; Demircan Sezer S; Nergiz Avcioglu S; Atakul T; Kurt Omurlu I; Yuksel H
J Matern Fetal Neonatal Med; 2017 Nov; 30(22):2653-2657. PubMed ID: 27838949
[TBL] [Abstract][Full Text] [Related]
50. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.
Nanjo S; Minami S; Mizoguchi M; Yamamoto M; Yahata T; Toujima S; Shiro M; Kobayashi A; Muragaki Y; Ino K
J Obstet Gynaecol Res; 2017 Dec; 43(12):1805-1814. PubMed ID: 28929598
[TBL] [Abstract][Full Text] [Related]
51. Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors.
Yang J; Pearl M; DeLorenze GN; Romero R; Dong Z; Jelliffe-Pawlowski L; Currier R; Flessel M; Kharrazi M
Am J Obstet Gynecol; 2016 Sep; 215(3):359.e1-9. PubMed ID: 27073062
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia.
Khalil A; Maiz N; Garcia-Mandujano R; Elkhouli M; Nicolaides KH
Ultrasound Obstet Gynecol; 2014 Oct; 44(4):402-10. PubMed ID: 24913462
[TBL] [Abstract][Full Text] [Related]
53. Maternal circulating levels of transforming growth factor-β superfamily and its soluble receptors in hypertensive disorders of pregnancy.
Xu YT; Shen MH; Jin AY; Li H; Zhu R
Int J Gynaecol Obstet; 2017 Jun; 137(3):246-252. PubMed ID: 28281288
[TBL] [Abstract][Full Text] [Related]
54. Exosomes From Women With Preeclampsia Induced Vascular Dysfunction by Delivering sFlt (Soluble Fms-Like Tyrosine Kinase)-1 and sEng (Soluble Endoglin) to Endothelial Cells.
Chang X; Yao J; He Q; Liu M; Duan T; Wang K
Hypertension; 2018 Dec; 72(6):1381-1390. PubMed ID: 30571229
[TBL] [Abstract][Full Text] [Related]
55. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
[TBL] [Abstract][Full Text] [Related]
56. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
[TBL] [Abstract][Full Text] [Related]
57. Accuracy of Soluble Endoglin for Diagnosis of Preeclampsia and its Severity.
Nikuei P; Rajaei M; Malekzadeh K; Nejatizadeh A; Mohseni F; AtashAbParvar A
Iran Biomed J; 2017 Sep; 21(5):312-30. PubMed ID: 28558439
[TBL] [Abstract][Full Text] [Related]
58. Association of increased cord blood soluble endoglin with the development of bronchopulmonary dysplasia in preterm infants with maternal preeclampsia.
Kim DH; Shin SH; Kim EK; Kim HS
Pregnancy Hypertens; 2018 Jul; 13():148-153. PubMed ID: 30177044
[TBL] [Abstract][Full Text] [Related]
59. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
[TBL] [Abstract][Full Text] [Related]
60. Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy.
Shahul S; Medvedofsky D; Wenger JB; Nizamuddin J; Brown SM; Bajracharya S; Salahuddin S; Thadhani R; Mueller A; Tung A; Lang RM; Arany Z; Talmor D; Karumanchi SA; Rana S
Hypertension; 2016 Jun; 67(6):1273-80. PubMed ID: 27113052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
